ERBB Stock Chart Fri, Jan 3rd, 2014

New Post Public Reply Private Reply Replies (0) Message Board
chartguy89
ERBB Stock Chart and Technical Analysis - Fri, Jan 3rd, 2014 $ERBB

Period  Moving Average  Price Change  Percent Change  Average Volume
5 Day  0.0024  +0.0012  +92.31%  158,338,750
20 Day  0.0016  +0.0014  +127.27%  48,168,414
50 Day  0.0016  +0.0007  +38.89%  26,036,041
100 Day  0.0018  -0.0004  -13.79%  27,455,225
200 Day  0.0031  -0.0042  -62.69%  27,802,094
Year to Date  0.0028  -0.0004  -13.79%  262,808,188

Period  Raw Stochastic  Stochastic %K  Stochastic %D  Average True Range
9 Day 40.00% 58.33% 70.56% 0.0007
14 Day 40.00% 59.04% 71.36% 0.0005
20 Day 41.67% 59.59% 71.54% 0.0005
50 Day 41.67% 59.59% 71.54% 0.0004
100 Day 41.67% 59.59% 65.26% 0.0005

Period  Relative Strength  Percent R  Historic Volatility  MACD Oscillator
9 Day 63.69% 60.00% 296.04% +0.0009
14 Day 63.18% 60.00% 257.35% +0.0011
20 Day 61.66% 58.33% 242.87% +0.0013
50 Day 53.55% 58.33% 174.12% +0.0013
100 Day 49.43% 58.33% 141.12% +0.0011

ERBB Stock Chart and Technical Analysis - Fri, Jan 3rd, 2014
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investigation Alerts for Spyre Therapeutics Investors Amid Concerns

Updated Category News Views 143

Investigation of Claims for Spyre Therapeutics Investors Pomerantz LLP is currently investigating claims on behalf of investors of Spyre Therapeutics, Inc. (NASDAQ: SYRE). The firm seeks to understand whether Spyre and its executives have potentially engaged in any unlawful business practices, specifically concerning securities fraud. Understanding the Securities Concerns...

Continue Reading
Natixis CIB's Pioneering Project Financing for Infrastructure

Updated Category News Views 126

Natixis CIB's Role in Groundbreaking Project Financing Natixis Corporate & Investment Banking (Natixis CIB) has taken a significant step in enhancing infrastructure development by serving as Joint Bookrunner and Joint Lead Arranger for a remarkable $281 million project financing. This financing initiative will support Ruta del Este, a concessionaire formed by ISA Vías to...

Continue Reading
Finch Therapeutics Moves to Delist from Nasdaq Amid Challenges

Updated Category News Views 177

Finch Therapeutics Plans Delisting from Nasdaq Finch Therapeutics Group, Inc. (Nasdaq: FNCH) has recently announced its decision to delist from The Nasdaq Stock Market, LLC. This move is part of a broader strategy aimed at navigating current market challenges and optimizing operational efficiency. The company is a leader in microbiome technology, boasting a strong...

Continue Reading
ModivCare: Exploring Recent Developments and Stockholder Rights

Updated Category News Views 269

Investigating the Latest Events Surrounding ModivCare Recent events surrounding ModivCare, Inc. have drawn considerable attention from the investor community and law firms alike. This scrutiny comes after a class action lawsuit from long-term shareholders, alleging the company's management may have misled investors about its ability to manage its financial health during a...

Continue Reading
Investors in Avantor, Inc. Urged to Act Before Key Deadline

Updated Category News Views 157

A Call to Action for Avantor, Inc. Investors Investors in Avantor, Inc. should take heed of an essential notification regarding a securities class action. As a market participant interested in Avantor, Inc. (NYSE: AVTR), your involvement could be crucial. This class action centers around stock purchases made during a specific timeframe that is intended to hold the company...

Continue Reading